New brain cancer drug combo enters first human tests
NCT ID NCT07185880
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 30 times
Summary
This study tests a new drug called MT-125 given together with standard radiation for people newly diagnosed with a fast-growing brain tumor called glioblastoma. The main goals are to find a safe dose and understand side effects. About 36 adults aged 18 and older with a specific type of glioblastoma (IDH wild-type, MGMT-unmethylated) can join. This is the first time MT-125 is tested in humans, so its safety and effectiveness are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic Hospital
RECRUITINGPhoenix, Arizona, 85054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic Hospital
RECRUITINGJacksonville, Florida, 32224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic Hospital
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.